The company's system for improving ECG analysis is already FDA-approved.
BSP - Biological Signal Processing Ltd. (TASE:BSP) has won US Food and Drug Administration (FDA) approval to market a new 2.0 version of its HyperQ stress system for diagnosis and monitoring of ischemic heart diseases. This latest version includes improved diagnostic capabilities and a more advanced user interface. BSP said the FDA clearance also covers the new system's advanced analysis of standard ECGs.
The earlier generation of the HyperQ system has been approved for marketing in the US and Europe, and trials are currently being held at a number of centers in Israel. BSP recently completed a pilot with Maccabi Health Services, which found that the company's system provided a better level of diagnosis than existing ECG monitors. The company's system will be trialed at a number of institutions in the US and Asia in the coming months.
BSP raised NIS 24 million in its IPO in 2006. The company's share has risen 39% since the IPO, giving it a current market cap of NIS 32 million.
Published by Globes [online], Israel business news - www.globes.co.il - on September 23, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007